ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

Several other equities analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research note on Tuesday, November 7th. Canaccord Genuity reiterated a “buy” rating on shares of ANI Pharmaceuticals in a research note on Thursday, November 2nd. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $68.25.

ANI Pharmaceuticals (NASDAQ:ANIP) opened at $61.83 on Tuesday. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $65.81. The stock has a market cap of $721.32, a price-to-earnings ratio of 18.48 and a beta of 2.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same period in the previous year, the business posted $1.09 EPS. The business’s revenue was up 25.0% compared to the same quarter last year. research analysts anticipate that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Downgraded by ValuEngine to “Hold”” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/14/ani-pharmaceuticals-inc-anip-downgraded-by-valuengine-to-hold.html.

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. BNP Paribas Arbitrage SA grew its holdings in shares of ANI Pharmaceuticals by 44.6% during the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 664 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth $197,000. Municipal Employees Retirement System of Michigan grew its holdings in shares of ANI Pharmaceuticals by 132.0% during the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 2,390 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth $226,000. Finally, Stevens Capital Management LP purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth $207,000. 56.48% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.